title: An evaluation of paroxetine in generalised social anxiety disorder.
abstract: It is estimated that social anxiety disorder affects approximately 13.3% individuals within the community at some point in their lifetime and is associated with significant functional impairment. A variety of drug groups have demonstrated efficacy in treating social anxiety disorder, including selective serotonin reuptake inhibitors (SSRIs). Paroxetine is an SSRI approved by the FDA and Health Canada for the treatment of a variety of psychiatric conditions. Paroxetine has been the most studied agent in social anxiety disorder and has been shown to be effective in short-term, fixed- and flexible-dose placebo-controlled trials, as well as in long-term treatment. The pharmacotherapy of social phobia will be reviewed, with a special focus on investigations with paroxetine.
authors.affiliation: Anxiety Disorders Clinic, 3G Clinic, McMaster University Medical Centre, Hamilton Health Sciences, Main St. W, Hamilton, ON, L8N 3Z5, Canada. vanamer@mcmaster.ca
authors.forename: Michael
authors.initials: M
authors.lastname: Van Ameringen
authors.forename: Catherine
authors.initials: C
authors.lastname: Mancini
authors.forename: Beth
authors.initials: B
authors.lastname: Patterson
authors.forename: Mark
authors.initials: M
authors.lastname: Bennett
mesh_terms: D001008:Anxiety Disorders / Q000188:drug therapy / Q000523:psychology; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data*; D004341:Drug Evaluation / Q000706:statistics & numerical data; D006801:Humans; D017374:Paroxetine / Q000627:therapeutic use*; D010698:Phobic Disorders / Q000188:drug therapy* / Q000523:psychology
chemical_list: D017374:Paroxetine